OBJECTIVE: Independent, prospective, multicenter, hospital-based cross-sectional studies were conducted across 5 countries in Asia, namely, Malaysia, Vietnam, Singapore, South Korea, and the Philippines. The objectives of these studies were to evaluate the prevalence of human papillomavirus (HPV) types (high risk and others including coinfections) in women with invasive cervical cancer (ICC) and high-grade precancerous lesions. METHODS: Women older than 21 years with a histologic diagnosis of ICC and cervical intraepithelial neoplasia [CIN 2 or 3 and adenocarcinoma in situ (AIS)] were enrolled. Cervical specimens were reviewed by histopathologists to confirm the presence of ICC or CIN 2/3/AIS lesion and tested with short PCR fragment 10-DNA enzyme immunoassay-line probe assay for 14 oncogenic HPV types and 11 non-oncogenic HPV types. The prevalence of HPV 16, HPV 18, and other high-risk HPV types in ICC [including squamous cell carcinoma (SCC) and adenocarcinoma/adenosquamous carcinoma (ADC/ASC)] and CIN 2/3/AIS was estimated. RESULTS: In the 5 Asian countries, diagnosis of ICC was confirmed in 500 women [SCC (n = 392) and ADC/ASC (n = 108)], and CIN 2/3/AIS, in 411 women. Human papillomavirus DNA was detected in 93.8% to 97.0% (84.5% for the Philippines) of confirmed ICC cases [94.0%-98.7% of SCC; 87.0%-94.3% (50.0% for the Philippines) of ADC/ASC] and in 93.7% to 100.0% of CIN 2/3/AIS. The most common types observed among ICC cases were HPV 16 (36.8%-61.3%), HPV 18 (12.9%-35.4%), HPV 52 (5.4%-10.3%), and HPV 45 (1.5%-17.2%), whereas among CIN 2/3/AIS cases, HPV 16 (29.7%-46.6%) was the most commonly observed type followed by HPV 52 (17.0%-66.7%) and HPV 58 (8.6%-16.0%). CONCLUSIONS: This article presents the data on the HPV prevalence, HPV type distribution, and their role in cervical carcinogenesis in 5 Asian countries. These data are of relevance to public health authorities for evaluating the existing and future cervical cancer prevention strategies including HPV-DNA testing-based screening and HPV vaccination in these Asian populations.
OBJECTIVE: Independent, prospective, multicenter, hospital-based cross-sectional studies were conducted across 5 countries in Asia, namely, Malaysia, Vietnam, Singapore, South Korea, and the Philippines. The objectives of these studies were to evaluate the prevalence of human papillomavirus (HPV) types (high risk and others including coinfections) in women with invasive cervical cancer (ICC) and high-grade precancerous lesions. METHODS:Women older than 21 years with a histologic diagnosis of ICC and cervical intraepithelial neoplasia [CIN 2 or 3 and adenocarcinoma in situ (AIS)] were enrolled. Cervical specimens were reviewed by histopathologists to confirm the presence of ICC or CIN 2/3/AIS lesion and tested with short PCR fragment 10-DNA enzyme immunoassay-line probe assay for 14 oncogenic HPV types and 11 non-oncogenic HPV types. The prevalence of HPV 16, HPV 18, and other high-risk HPV types in ICC [including squamous cell carcinoma (SCC) and adenocarcinoma/adenosquamous carcinoma (ADC/ASC)] and CIN 2/3/AIS was estimated. RESULTS: In the 5 Asian countries, diagnosis of ICC was confirmed in 500 women [SCC (n = 392) and ADC/ASC (n = 108)], and CIN 2/3/AIS, in 411 women. Human papillomavirus DNA was detected in 93.8% to 97.0% (84.5% for the Philippines) of confirmed ICC cases [94.0%-98.7% of SCC; 87.0%-94.3% (50.0% for the Philippines) of ADC/ASC] and in 93.7% to 100.0% of CIN 2/3/AIS. The most common types observed among ICC cases were HPV 16 (36.8%-61.3%), HPV 18 (12.9%-35.4%), HPV 52 (5.4%-10.3%), and HPV 45 (1.5%-17.2%), whereas among CIN 2/3/AIS cases, HPV 16 (29.7%-46.6%) was the most commonly observed type followed by HPV 52 (17.0%-66.7%) and HPV 58 (8.6%-16.0%). CONCLUSIONS: This article presents the data on the HPV prevalence, HPV type distribution, and their role in cervical carcinogenesis in 5 Asian countries. These data are of relevance to public health authorities for evaluating the existing and future cervical cancer prevention strategies including HPV-DNA testing-based screening and HPV vaccination in these Asian populations.
Authors: Yeoun Eun Sung; Eun Young Ki; Youn Soo Lee; Soo Young Hur; Ahwon Lee; Jong Sup Park Journal: J Gynecol Oncol Date: 2016-07-01 Impact factor: 4.401
Authors: Katsiaryna Holl; Andrzej M Nowakowski; Ned Powell; W Glenn McCluggage; Edyta C Pirog; Sabrina Collas De Souza; Wiebren A Tjalma; Mats Rosenlund; Alison Fiander; Maria Castro Sánchez; Vasileia Damaskou; Elmar A Joura; Benny Kirschner; Robert Koiss; John O'Leary; Wim Quint; Olaf Reich; Aureli Torné; Michael Wells; Lukas Rob; Larisa Kolomiets; Anco Molijn; Alevtina Savicheva; Elena Shipitsyna; Dominique Rosillon; David Jenkins Journal: Int J Cancer Date: 2015-07-14 Impact factor: 7.396
Authors: Mariana T Rezende; Raniere Silva; Fagner de O Bernardo; Alessandra H G Tobias; Paulo H C Oliveira; Tales M Machado; Caio S Costa; Fatima N S Medeiros; Daniela M Ushizima; Claudia M Carneiro; Andrea G C Bianchi Journal: Sci Data Date: 2021-06-10 Impact factor: 6.444
Authors: Anna Melissa Guerrero; Anne Julienne Genuino; Melanie Santillan; Naiyana Praditsitthikorn; Varit Chantarastapornchit; Yot Teerawattananon; Marissa Alejandria; Jean Anne Toral Journal: BMC Public Health Date: 2015-07-30 Impact factor: 3.295
Authors: María Guadalupe Flores-Miramontes; Luis Alberto Torres-Reyes; Liliana Alvarado-Ruíz; Salvador Angel Romero-Martínez; Verenice Ramírez-Rodríguez; Luz María Adriana Balderas-Peña; Verónica Vallejo-Ruíz; Patricia Piña-Sánchez; Elva Irene Cortés-Gutiérrez; Luis Felipe Jave-Suárez; Adriana Aguilar-Lemarroy Journal: Virol J Date: 2015-10-06 Impact factor: 4.099